- Dicerna Pharmaceuticals (NASDAQ:DRNA) initiated with Outperform rating and $14 (66% upside) price target by Evercore ISI.
- IDEXX Labs (NASDAQ:IDXX) initiated with Overweight rating and $200 (15% upside) price target by Piper Jaffray.
- Molina Healthcare (NYSE:MOH) upgraded to Overweight by JPMorgan.
- Gilead Sciences (NASDAQ:GILD) upgraded to Outperform by Wells Fargo.
- Spark Therapeutics (NASDAQ:ONCE) downgraded to Underperform with a price target of $35 (34% downside risk) by Wedbush. Shares are down 5% premarket on light volume.
- TiGenix (NASDAQ:TIG) downgraded to Neutral by BTIG Research.
- Allscripts Healthcare (NASDAQ:MDRX) downgraded to Hold by SunTrust.
- Eli Lilly (NYSE:LLY) downgraded to Neutral by Goldman Sachs.